ReviewSeminars in nephrology2017
Clinical Genetic Testing for APOL1: Are we There Yet?
Review in Seminars in nephrology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 32 citations in OpenAlex.
- A Scoping Review of Toolkits Addressing Ethical Issues in Health Registry and Clinical Research Enrollment Among African Americans With CKD.Kidney medicine · 2026Review
- Article
- APOL1 polymorphisms are not influencing acute coronary syndrome risk in Czech males.Molecular genetics & genomic medicine · 2024Article
- Phenome-wide analysis reveals epistatic associations between APOL1 variants and chronic kidney disease and multiple other disorders.EBioMedicine · 2024Article
- Race, Ancestry, and Genetic Risk for Kidney Failure.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2022Article
- The Evolving Role of Diagnostic Genomics in Kidney Transplantation.Kidney international reports · 2022Review
- Precision medicine implementation challenges forFrontiers in genetics · 2022Article
- Impact of education on APOL1 testing attitudes among prospective living kidney donors.Clinical transplantation · 2022Article
- APOL1 risk variants and the development of HIV-associated nephropathy.The FEBS journal · 2021Review
- Opinions of African American adults about the use of apolipoprotein L1 (ApoL1) genetic testing in living kidney donation and transplantation.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2021Article
- Association Between APOL1 Genotype and Kidney Diseases and Annual Kidney Function Change: A Systematic Review and Meta-Analysis of the Prospective Studies.International journal of nephrology and renovascular disease · 2021Review
- Inherited glomerular diseases in the gilded age of genomic advancements.Pediatric nephrology (Berlin, Germany) · 2020Review
- Genetic Testing forClinical journal of the American Society of Nephrology : CJASN · 2020Article
- Frequency of ClinVar Pathogenic Variants in Chronic Kidney Disease Patients Surveyed for Return of Research Results at a Cleveland Public Hospital.Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · 2020Article
- Cases in Precision Medicine: APOL1 and Genetic Testing in the Evaluation of Chronic Kidney Disease and Potential Transplant.Annals of internal medicine · 2019Article
- APOL1 Genetic Testing in Living Kidney Transplant Donors.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2019Review
- Racial disparities in end-stage renal disease in a high-risk population: the Southern Community Cohort Study.BMC nephrology · 2019Article
- You Are Just Now Telling Us About This? African American Perspectives of Testing for Genetic Susceptibility to Kidney Disease.Journal of the American Society of Nephrology : JASN · 2019Article
- Biomarkers in Solid Organ Transplantation.Clinics in laboratory medicine · 2019Review
- African American Living Donors' Attitudes About APOL1 Genetic Testing: A Mixed Methods Study.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
End-stage renal disease (ESRD) disproportionately affects African Americans, who are two to four times more likely than European Americans to develop ESRD. Two independent variants of the apolipoprotein L1 (APOL1) gene, G1 and G2, have been associated with a 7- to 10-fold greater risk of developing nondiabetic ESRD in African Americans. Those who inherit two risk variants (G1/G1, G2/G2, or G1/G2) are also more likely to develop ESRD at a younger age and to have progression of chronic kidney disease. Currently, it is not known what proportion of persons with high-risk genotypes will develop ESRD in the general population, the exact mechanism of injury for APOL1-related risk, its relation to environmental exposures, or whether patients with comorbid conditions are more likely to develop ESRD. To address the above uncertainties, research that includes assessment of APOL1 status is needed before guidelines for general testing can be endorsed. Currently, APOL1 testing has been proposed as part of kidney transplant protocols both for living donors and recipients. However, because of uncertainties regarding the clinical implications of APOL1 variants, testing could generate confusion, anxiety, or stigma. Multiple forms of evidence, including the views of community members, are needed to support responsible approaches to providing information about APOL1 status as part of clinical care or in population screening. Informed consent with subsequent counseling regarding the risks and benefits of APOL1 testing should be considered for patients at high risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.